The Role of Interventional Treatment on Hepatocellular Carcinoma Combined with Portal Vein Tumor Thrombosis

YAO Wenwo,YAN Zhiping,WANG Jianhua,WANG Xiaolin,MA jianzhong,CHEN yi

DOI: https://doi.org/10.3969/j.issn.1008-6358.2007.06.025

2007-01-01

Abstract:Objective:To study the indication and method of interventional treatment on hepatocellular carcinoma combined with portal trunk and/or first level branch tumor thrombosis.Methods:25 patients with primary liver cancer combined with portal trunk and/or first level branch tumor thrombosis received transcatheter arterial chemoembolization,and partial of them received portal vein stent deployment.Results:A total of 46 procedures were performed in 25 patients,and portal vein stent were deployed in 5 patients.One week after the procedure,11 cases elevated from A to B.1 case elevated from A to C,and 2 cases elevated from B to C according to Child-Pugh classification scheme.One patient developed hepatic encephalopathy 2 days after the procedure.Patency of portal vein stent was maintained until death in4 patients,1 patient was lost follow-up.Surival time ranged from 3 to I5 months(meant 6,4 months),Conclusion:TACE and portal vein stent deployment are safe and effec- tive treatment on primary liver cancer combined with portal trunk and/or first level branch tumor thrombosis,on condition that we have the proper indication and method.